Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy-Reference-Cited by-同舟云学术

Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy

Published:2024-01-29 Issue:6 Volume:18 Page:5152-5166
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Liu Jing¹²^ORCID,Jiang Xiaomin¹^ORCID,Li Youyou¹,Yang Kaiting²,Weichselbaum Ralph R.²,Lin Wenbin¹²^ORCID

Affiliation:

1. Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, United States

2. Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, 5758 South Maryland Avenue, Chicago, Illinois 60637, United States

Funder

National Institutes of Health

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.3c12678

Reference52 articles.

1. Pembrolizumab versus Ipilimumab in Advanced Melanoma

2. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

3. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

5. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment;Drug Discovery Today;2024-09

2. The current role of dendritic cells in the progression and treatment of colorectal cancer;Cancer Biology & Medicine;2024-08-22

3. Mitochondria‐Targeted Multifunctional Nanoparticles Combine Cuproptosis and Programmed Cell Death‐1 Downregulation for Cancer Immunotherapy;Advanced Science;2024-07-16

4. How to optimize the immune checkpoint blockade therapy for cancers?;Oncologie;2024-03-18